全文获取类型
收费全文 | 2604604篇 |
免费 | 215458篇 |
国内免费 | 17236篇 |
专业分类
耳鼻咽喉 | 37125篇 |
儿科学 | 77724篇 |
妇产科学 | 69360篇 |
基础医学 | 358784篇 |
口腔科学 | 72541篇 |
临床医学 | 242538篇 |
内科学 | 500865篇 |
皮肤病学 | 50937篇 |
神经病学 | 212431篇 |
特种医学 | 104405篇 |
外国民族医学 | 1002篇 |
外科学 | 388862篇 |
综合类 | 92566篇 |
一般理论 | 1044篇 |
预防医学 | 205770篇 |
眼科学 | 62482篇 |
药学 | 200640篇 |
132篇 | |
中国医学 | 15110篇 |
肿瘤学 | 142980篇 |
出版年
2021年 | 21598篇 |
2019年 | 26438篇 |
2018年 | 29997篇 |
2017年 | 24992篇 |
2016年 | 25680篇 |
2015年 | 31923篇 |
2014年 | 45061篇 |
2013年 | 61462篇 |
2012年 | 84590篇 |
2011年 | 89647篇 |
2010年 | 53329篇 |
2009年 | 49418篇 |
2008年 | 80246篇 |
2007年 | 84696篇 |
2006年 | 85238篇 |
2005年 | 83494篇 |
2004年 | 77061篇 |
2003年 | 73831篇 |
2002年 | 72088篇 |
2001年 | 116449篇 |
2000年 | 120634篇 |
1999年 | 102691篇 |
1998年 | 29354篇 |
1997年 | 27097篇 |
1996年 | 26211篇 |
1995年 | 26834篇 |
1994年 | 25084篇 |
1993年 | 22804篇 |
1992年 | 80916篇 |
1991年 | 77834篇 |
1990年 | 74738篇 |
1989年 | 71830篇 |
1988年 | 66680篇 |
1987年 | 65570篇 |
1986年 | 61952篇 |
1985年 | 58873篇 |
1984年 | 44465篇 |
1983年 | 37794篇 |
1982年 | 22934篇 |
1979年 | 41400篇 |
1978年 | 29001篇 |
1977年 | 24288篇 |
1976年 | 22746篇 |
1975年 | 23912篇 |
1974年 | 29612篇 |
1973年 | 28028篇 |
1972年 | 26216篇 |
1971年 | 24159篇 |
1970年 | 22749篇 |
1969年 | 21067篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Dimitrios Moris MD MSc PhD Manisha Palta MD Charles Kim MD Peter J. Allen MD Michael A. Morse MD Michael E. Lidsky MD 《CA: a cancer journal for clinicians》2023,73(2):198-222
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially curative treatment; and, after resection, a median survival of 53 months has been reported when sequenced with adjuvant capecitabine. For the 70%–80% of patients who present with locally unresectable or distant metastatic disease, systemic therapy may delay progression, but survival remains limited to approximately 1 year. For the past decade, doublet chemotherapy with gemcitabine and cisplatin has been considered the most effective first-line regimen, but results from the recent use of triplet regimens and even immunotherapy may shift the paradigm. More effective treatment strategies, including those that combine systemic therapy with locoregional therapies like radioembolization or hepatic artery infusion, have also been developed. Molecular therapies, including those that target fibroblast growth factor receptor and isocitrate dehydrogenase, have recently received US Food and Drug Administration approval for a defined role as second-line treatment for up to 40% of patients harboring these actionable genomic alterations, and whether they should be considered in the first-line setting is under investigation. Furthermore, as the oncology field seeks to expand indications for immunotherapy, recent data demonstrated that combining durvalumab with standard cytotoxic therapy improved survival in patients with ICC. This review focuses on the current and future strategies for ICC treatment, including a summary of the primary literature for each treatment modality and an algorithm that can be used to drive a personalized and multidisciplinary approach for patients with this challenging malignancy. 相似文献
2.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
3.
4.
5.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
6.
7.
8.
9.